Skip to content
Head to head

Harmony Biosciences vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: HRMY · VRTX

Updated 9 minutes ago

1-year performance, rebased to 100

HRMY -4.1%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
HRMYVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price32.59515.02
Change today-1.18%-1.08%
1-year return-2.4%+22.0%
Market cap$1.91B$130.58B
52-week range25.90 – 43.49412.27 – 568.67
Valuation
P/E (TTM)10.7933.14
P/E percentile, own 5-yr range17th99th
P/B1.786.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)2.7115.32
Net profit (TTM)$159.14M$3.88B
Revenue (TTM)$989.36M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+12.3%+11.8%
Gross margin74.0%85.5%
Operating margin22.2%33.1%
Net margin18.1%30.7%
Free cash flow (TTM)$322.93M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership114.3%96.8%
Insider activity (12mo)24 buy / 23 sell28 buy / 22 sell
Short interest (% of float)11.4%1.9%
Analyst consensus62% buy / 25% hold / 12% sell (8)95% buy / 5% hold (21)
Analyst price target$48 (+46%)$624 (+21%)
StockVane view
StockVane Quant RatingD (37)C (68)
Company
Employees2936,400
Founded20171989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.